Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma

This study has been completed.
Sponsor:
Collaborator:
Glenmark Pharmaceuticals S.A.
Information provided by (Responsible Party):
Glenmark Pharmaceuticals Ltd. India
ClinicalTrials.gov Identifier:
NCT01436890
First received: September 14, 2011
Last updated: June 20, 2013
Last verified: June 2013

September 14, 2011
June 20, 2013
October 2011
April 2013   (final data collection date for primary outcome measure)
Change in Forced Expiratory Volume in One Second (FEV1) from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01436890 on ClinicalTrials.gov Archive Site
  • Change in morning pre-dose Forced Vital Capacity (FVC) from baseline to week 12 [ Time Frame: baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Area under the curve of Forced Expiratory Volume in One Second (FEV1) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change in asthma day time symptom score from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Frequency and severity of asthma exacerbations during treatment period [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
  • Change in investigator global impression from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
    An investigator-rated test measured on a 7-point scale, used to rate change in a patient's condition over the course of the study.
  • Change in patient global impression from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
    A patient-rated test measured on a 7-point scale, used to rate change in a patient's condition over the course of the study.
  • Change in morning pre-dose Peak Expiratory Flow (PEF) from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
  • Change in morning pre-dose PEF25-75% (Forced expiratory flow 25-75%) from baseline to week 12 [ Time Frame: Baseline to 12 weeks ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
A Clinical Trial to Study the Effects of Revamilast in Patients With Chronic Persistent Asthma
A Phase II, 12-week Randomized, Double-blind, Triple Dummy, Parallel Group, Placebo-controlled, Dose Range Finding Study to Evaluate Safety, Tolerability and Efficacy of Revamilast in Patients With Chronic Persistent Asthma

Asthma is a common, chronic inflammatory disease of the bronchial airways, with a reported prevalence in most industrialized countries of between 5 to 10 % of the adult population. Asthma is clinically characterized by repeated episodes of wheezing, breathlessness, chest tightness, and coughing; usually in the presence of variable airflow obstruction that is often reversible either spontaneously or with treatment (The Global Initiative for Asthma (GINA), 2009).

Drug treatment of asthma has focused on anti-inflammatory therapy in all but the mildest, intermittent cases. Inhaled corticosteroids have been shown to be anti-inflammatory in asthma, but chronic use of these agents may be associated with a range of side effects, especially at high doses. In asthma, there remains a need for the development of novel anti-inflammatory therapies that are at least equally effective and possess a superior safety profile in comparison to corticosteroids.

This is a randomized, double-blind, triple dummy, placebo controlled, parallel group, dose ranging study. The study will be conducted in adult patients with a diagnosis of chronic persistent asthma with an Forced Expiratory Volume in one second(FEV1) of 50% to 80% of the predicted value. Study will enroll 448 patients globally (278 from India) across different centers.

Patients will be recruited after providing written informed consent. After screening and run in period, patient will be randomized (patient meeting randomization criteria) in 1:1:1:1 ratio to receive either one of the three dose regimens of revamilast or placebo.

The primary objective of the study is to evaluate the effect of revamilast on lung function as assessed by Forced Expiratory Volume in one second (FEV1) after the therapy (12 weeks). Secondary objective includes area under curve for FEV1, Change in asthma symptoms, patient / investigator's global assessments and safety. Patients will be followed for safety and efficacy assessment at week 1, 4, 8 12 and 14 after start of therapy.

Not Provided
Interventional
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Asthma
  • Drug: Revamilast
    Tablet. Low dose, Once daily for 12 weeks
  • Drug: Revamilast
    Medium dose, Once daily for 12 weeks
  • Drug: Revamilast
    High dose, Once daily for 12 weeks
  • Drug: Placebo
    Placebo tablet in triple dummy format, Once daily for 12 weeks
  • Experimental: Low dose
    Low dose revamilast
    Intervention: Drug: Revamilast
  • Experimental: Medium dose
    Medium dose Revamilast
    Intervention: Drug: Revamilast
  • Experimental: High dose
    High dose Revamilast
    Intervention: Drug: Revamilast
  • Placebo Comparator: Placebo
    Matching placebo in triple dummy format
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
273
April 2013
April 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The patient provides written informed consent to participate in the study
  2. Male or female patient aged 18 to 65 years
  3. Documented diagnosis of asthma
  4. Forced Expiratory Volume in One Second (FEV1) between 50% and 80% of the predicted value
  5. Patient judged by the investigator to be in otherwise good stable health based on medical history, physical examination, and routine laboratory data
  6. Female participants must have a negative pregnancy test at screening visit
  7. Males must agree to use barrier contraception while on study medication and for 90 days after taking the last dose of study medication

Exclusion Criteria:

  1. Pregnant or lactating women
  2. Female subjects on hormone replacement therapy or hormonal contraceptives
  3. Suffering from relevant lung diseases (other than asthma) causing impairment in lung function
  4. Past smoker with a history of ≥10 pack per year or current smoker
  5. Recent change in the patient's usual asthma treatment
  6. Patients with risk factors for asthma exacerbation during the study, including (any of the following):

    • Current requirement for > 8 puffs per day of reliever medication.
    • Hospitalization for asthma
    • Treatment with systemic corticosteroid therapy within 3 months
  7. Evidence of current or recent neoplastic disease
  8. Clinically significant cardiovascular, haematological, endocrine, neurological, gastrointestinal, psychiatric, metabolic, immunologic, infectious, hepatic, renal, gynaecological disease or other condition that the investigator considers detrimental to the patient's participation in the study or that may prevent the successful completion of the study
  9. Positive serology for an infectious disease (including hepatitis B or C) at screening and known case of human immunodeficiency virus [HIV]
  10. Patients who have been hospitalized for any psychiatric illness in the past year, or are diagnosed with major depression
  11. Clinically significant ECG Abnormality at baseline
  12. Patients with documented or suspected or current history of alcohol and drug abuse
  13. Patients who have undergone lung surgery in the previous year
  14. Participation in an investigational drug trial during 30 days preceding screening
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
Czech Republic,   India,   Poland,   Russian Federation,   United Kingdom
 
NCT01436890
GRC 4039-204, 2011-000270-57
No
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals Ltd. India
Glenmark Pharmaceuticals S.A.
Study Director: Dr Ballari Brahmachari Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd. India
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP